So, exciting opportunities with EGFR and met ADCs [antibody drug conjugates] as well as EGFR and CD3 T-cell engagers in the ...

The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

Greater ORR of 55.6% was seen in patients with EGFR sensitizing and T790M double mutations (78% had received third-generation EGFR-TKI treatment in prior lines of therapy). Sunvozertinib was ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.

This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...